barbara klencke chief development officer pronai therapeutics timesjavascript is disabled market profiles login sign up login sign up   edit person barbara klencke chief development officer at pronai therapeutics location san francisco bay area add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop barbara klencke chief development officer at pronai therapeutics location san francisco bay area add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop barbara klencke md is senior vice president development responsible for the development functions of biometrics clinical operations clinical science medical writing regulatory affairs clinical pharmacology and project management she joined onyx in  after serving as group medical director in product development oncology at genentech inc where she led clinical teams on molecules that have since made great advances for patients as marketed oncology medicines dr klencke’s interest in drug development began after a  year career delivering patient care initially in nursing and then in medicine including many years teaching medicine and pursing clinical research at the university of california at san francisco where she also completed her training in hematology and oncology she earned her medical degree at the university of california at davis and her bachelor’s degree in nursing from indiana university at bloomington  companies in career na related markets  colleagues na related investments alias na industry rd in biotech environmental and various industries no marketing product yet tags oncology clinical trials clinical development topics of influence na na careers achievements investments related people edit view all barbara klenckecareer  jun pronai therapeutics chief development officer jan to jun onyx pharmaceuticals sr vp development 0 to jan genentech group medical director aug0 to jul0 chiron novartis medical director jun9 to jul0 ucsf medical center assistant professor of medicine competencies edit view all barbara klenckeeducation  university of california davis  school of medicine medicine edit barbara klenckeachievements and recognitions add milestone no milestones has been recorded for barbara klencke edit barbara klenckelinks add link no links has been recorded for barbara klencke barbara klenckeinvestmentsacquisitions no investments has been recorded for barbara klencke barbara klenckeinvestments representing others no investment reps has been recorded for barbara klencke barbara klenckerelated people colleagues at pronai therapeutics christian hassig senior vice president of research jun keith anderson svp technical operations  gregg smith vice president preclinical nov diane gardiner vice president human resources feb view all peers  jeff packman chief development officer of clementia pharmaceuticals steven gelone chief development officer of nabriva therapeutics ken bartizal chief development officer of cidara therapeutics steve wigginton chief development officer of evolent health roni mamluk chief development officer of chiasma lawrence friedhoff chief development officer of axovant sciences view all barbara klenckerecommended market profiles  healthcare venture deals    employees  companies healthcare ipo companies  or more employees  companies barbara klencke  onyx pharmaceuticals  inc  zoominfocom pronai appoints dr barbara klencke as chief development officer pronai appoints dr barbara klencke as chief development officer jun    et from pronai therapeutics inc vancouver june   prnewswire  pronai therapeutics inc a clinicalstage oncology company pioneering a novel class of therapeutics based on its proprietary dnai technology platform today announced that it has appointed dr barbara klencke md as chief development officer dr klencke is an accomplished oncology drug developer with a demonstrable track record of success having made substantial contributions to the development and approval of numerous significant oncology products including kyprolis kadcyla avastin and tarceva barbara has extensive experience leading the strategic development of novel oncology compounds and advancing these products successfully through the registration process said dr nick glover president and ceo of pronai therapeutics our ability to attract such a highlyrespected strategic drug development expert as dr klencke reflects the scope of the opportunity for our lead dnaibased cancer drug pnt and for the broader potential of the dnai technology platform underlying our novel approach to treating cancer previously dr klencke served as the senior vice president development at onyx pharmaceuticals a subsidiary of amgen inc from january  to june  and prior to that was the group medical director in product development oncology at genentech inc having joined the company in july 0 in this period she led a variety of oncology programs including those for kyprolis carfilzomib kadcyla adotrastuzumab emtansine avastin bevacizumab and tarceva erlotinib prior to that dr klencke served as the medical director at chiron corporation a biotechnology company later acquired by novartis international ag and as an assistant professor of medicine at the university of california san francisco medical center dr klencke holds a bs from indiana university and an md from the university of california davis of the many oncology programs ive been involved with pronais lead therapeutic targeting bcl stands out as a novel and compelling product candidate with the potential to impact a wide range of cancers added dr klencke ive also been highly impressed by the quality of the team pronai has assembled to advance pnt and i am committed to working closely with them to drive this program forward about pronai therapeuticspronai therapeutics is a clinicalstage oncology company pioneering a novel class of therapeutics based on its proprietary dnai technology platform for patients with cancer and hematological diseases pronais lead dnai product candidate pnt is designed to treat cancers that overexpress bcl an important and validated oncogene known to be dysregulated in many types of cancer pronai is pursuing a multifaceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of pnt pronai recently initiated wolverine a phase  trial evaluating pnt for the treatment of relapsed or refractory diffuse large bcell lymphoma for more information please visit wwwpronaicom source pronai therapeutics inc view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more jul    et preview pronai therapeutics announces pricing of initial public offering jun    et preview pronai appoints dr nicole onetto and mr robert pelzer to its board of directors my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search barbara klencke sierra oncology inc profile  biography  bloomberg feedback barbara klencke chief development officer sierra oncology inc career history chief development officer sierra oncology inc 7present chief development officer pronai therapeutics inc 7 website wwwsierraoncologycom corporate information address  west georgia street vancouver bc vc e canada phone 0 fax  web url wwwsierraoncologycom from the web personal information education indiana university bachelors degree university of california md sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data page not found  thestreet action alerts plus access aapjim cramers best stocks for 7charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for 7 commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use 9 thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street page not found sorry the page youre looking for is not available you might want to try our homepage our most popular stories 97 thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers find a doctor symptom checker conditions medications procedures and hospitals  itriagehealthcom pronai appoints dr barbara klencke as chief development officer fr × member sign in online member centre cision communications cloud cision pr edition cisionpoint mediasource monitoringevaluation visible intelligence fastfinder my cnw cnw access register for my cnw close × search search go  advanced search close see more news releases in biotechnology medical pharmaceuticals personnel announcements pronai appoints dr barbara klencke as chief development officer vancouver june   cnw  pronai therapeutics inc a clinicalstage oncology company pioneering a novel class of therapeutics based on its proprietary dnai technology platform today announced that it has appointed dr barbara klencke md as chief development officer dr klencke is an accomplished oncology drug developer with a demonstrable track record of success having made substantial contributions to the development and approval of numerous significant oncology products including kyprolis kadcyla avastin and tarceva barbara has extensive experience leading the strategic development of novel oncology compounds and advancing these products successfully through the registration process said dr nick glover president and ceo of pronai therapeutics our ability to attract such a highlyrespected strategic drug development expert as dr klencke reflects the scope of the opportunity for our lead dnaibased cancer drug pnt and for the broader potential of the dnai technology platform underlying our novel approach to treating cancer previously dr klencke served as the senior vice president development at onyx pharmaceuticals a subsidiary of amgen inc from january  to june  and prior to that was the group medical director in product development oncology at genentech inc having joined the company in july 0 in this period she led a variety of oncology programs including those for kyprolis carfilzomib kadcyla adotrastuzumab emtansine avastin bevacizumab and tarceva erlotinib prior to that dr klencke served as the medical director at chiron corporation a biotechnology company later acquired by novartis international ag and as an assistant professor of medicine at the university of california san francisco medical center dr klencke holds a bs from indiana university and an md from the university of california davis of the many oncology programs ive been involved with pronais lead therapeutic targeting bcl stands out as a novel and compelling product candidate with the potential to impact a wide range of cancers added dr klencke ive also been highly impressed by the quality of the team pronai has assembled to advance pnt and i am committed to working closely with them to drive this program forward about pronai therapeuticspronai therapeutics is a clinicalstage oncology company pioneering a novel class of therapeutics based on its proprietary dnai technology platform for patients with cancer and hematological diseases pronais lead dnai product candidate pnt is designed to treat cancers that overexpress bcl an important and validated oncogene known to be dysregulated in many types of cancer pronai is pursuing a multifaceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of pnt pronai recently initiated wolverine a phase  trial evaluating pnt for the treatment of relapsed or refractory diffuse large bcell lymphoma for more information please visit wwwpronaicom source pronai therapeutics inc for further information james smith vice president corporate affairs pronai therapeutics 0 jsmithpronaicom release contains wide tables view fullscreen organization profile pronai therapeutics inc more on this organization custom packages browse our custom packages or build your own to meet your unique communications needs start today cnw membership fill out a cnw membership form or contact us at  77 9790 learn about cnw services request more information about cnw products and services or call us at  77 9790   pronai therapeutics inc appoints dr barbara klencke as chief development officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km0  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       pronai therapeutics inc appoints dr barbara klencke as chief development officer tweet  7 am vancouver june   prnewswire  pronai therapeutics inc a clinicalstage oncology company pioneering a novel class of therapeutics based on its proprietary dnai technology platform today announced that it has appointed dr barbara klencke md as chief development officer dr klencke is an accomplished oncology drug developer with a demonstrable track record of success having made substantial contributions to the development and approval of numerous significant oncology products including kyprolis kadcyla avastin and tarceva barbara has extensive experience leading the strategic development of novel oncology compounds and advancing these products successfully through the registration process said dr nick glover president and ceo of pronai therapeutics our ability to attract such a highlyrespected strategic drug development expert as dr klencke reflects the scope of the opportunity for our lead dnaibased cancer drug pnt and for the broader potential of the dnai technology platform underlying our novel approach to treating cancerpreviously dr klencke served as the senior vice president development at onyx pharmaceuticals a subsidiary of amgen inc from january  to june  and prior to that was the group medical director in product development oncology at genentech inc having joined the company in july 0 in this period she led a variety of oncology programs including those for kyprolis carfilzomib kadcyla adotrastuzumab emtansine avastin bevacizumab and tarceva erlotinib prior to that dr klencke served as the medical director at chiron corporation a biotechnology company later acquired by novartis international ag and as an assistant professor of medicine at the university of california san francisco medical center dr klencke holds a bs from indiana university and an md from the university of california davisof the many oncology programs ive been involved with pronais lead therapeutic targeting bcl stands out as a novel and compelling product candidate with the potential to impact a wide range of cancers added dr klencke ive also been highly impressed by the quality of the team pronai has assembled to advance pnt and i am committed to working closely with them to drive this program forwardabout pronai therapeuticspronai therapeutics is a clinicalstage oncology company pioneering a novel class of therapeutics based on its proprietary dnai technology platform for patients with cancer and hematological diseases pronais lead dnai product candidate pnt is designed to treat cancers that overexpress bcl an important and validated oncogene known to be dysregulated in many types of cancer pronai is pursuing a multifaceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of pnt pronai recently initiated wolverine a phase  trial evaluating pnt for the treatment of relapsed or refractory diffuse large bcell lymphoma for more information please visit wwwpronaicom source pronai therapeutics inc help employers find you check out all the jobs and post your resume read at biospacecom related news pronai therapeutics inc files registration statement for proposed initial public offering incyte incy reorganizes and shakes up management to drive growth pronai therapeutics inc strengthens leadership team opens vancouver corporate headquarters cipla executives resigning but company says nothing amiss pronai therapeutics inc appoints dr nicole onetto and mr robert pelzer to its board of directors pronutria biosciences announces key additions to executive team pronai therapeutics inc initiates phase  trial of pnt in patients with relapsed or refractory diffuse large bcell lymphoma dlbcl exastrazeneca plc azn cmo takes helm at tiny syndax marina biotech inc mrna reports that licensee pronai therapeutics inc presented interim phase  data on its bcltargeting dnai® therapeutic at american society of hematology  axogen inc axgn chief marketing officer named ceo of privatelyheld life sciences company please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • sierra oncology formerly known as pronai therapeutics inc   • biotechpharma  personnel